dalbavancin (Xydalba®) is accepted for restricted use within NHS Scotland.
Indication under review: treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
SMC restriction:
In two phase III double-blind studies of patients with ABSSSI, dalbavancin was non-inferior to the comparator for clinical response at end of treatment in the clinically evaluable population.
Drug Name: | dalbavancin (Xydalba) |
---|---|
SMC Drug ID: | 1105/15 |
Manufacturer: | Allergan/Actavis |
Indication: | Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. |
BNF Category: | |
Sub Category: | 5.1 Antibacterial drugs |
Submission Type: | Full submission |
Status: | Restricted |
Date Advice Published: | 16 January 2017 |
To read more Press Release articles, click here.
About FirstWord Pharma | Refer a Colleague | Upgrade Your FirstWord Pharma | Contact FirstWord Pharma | FirstWord Reports
Advertise with FirstWord Pharma | Industry Partner Showcase
All Contents Copyright © 2019 Doctor's Guide Publishing Limited. All Rights Reserved.
Terms of Use | Privacy Policy